Liraglutide Cost in North Carolina 2026: Cash Pay, Insurance, Medicaid, and Compounded Options

How Much Does Liraglutide Cost in North Carolina Without Insurance?

Without insurance, North Carolinians pay between $900 and $1,349 per month for brand-name liraglutide depending on which pharmacy they use and which product they fill. The Novo Nordisk wholesale acquisition cost sits at approximately $1,349 per month for a standard supply of Saxenda (3.0 mg/dose for weight management) or Victoza (1.8 mg/dose for type 2 diabetes). Retail pharmacies typically discount from that list price, landing at a statewide cash-pay average near $900 per month in 2026.

GoodRx and similar discount platforms can pull prices at large North Carolina chains, including CVS, Walgreens, and Walmart, down further, sometimes into the $700 to $850 range for a 30-day supply of Victoza 18 mg/3 mL pens. Those prices shift weekly, so pulling a real-time quote at the pharmacy counter before paying is always worth the 90 seconds it takes.

The liraglutide molecule itself has been off patent since the early 2020s in several international markets, yet no FDA-approved generic liraglutide product existed in the United States as of mid-2025. The FDA's Office of Generic Drugs maintains a searchable database of approved generics; as of this writing, liraglutide returns no approved ANDA entries. [1] That absence keeps brand competition nonexistent and cash prices high.

The SCALE Obesity trial (N=3,731) published in the New England Journal of Medicine demonstrated that liraglutide 3.0 mg produced a mean weight loss of 8.4% at 56 weeks versus 2.5% with placebo (P<0.001). [2] That clinical evidence underpins why so many North Carolina patients and clinicians pursue access at any price point they can manage.

Does North Carolina Medicaid Cover Liraglutide?

North Carolina Medicaid covers liraglutide for type 2 diabetes management but does not cover it for chronic weight management as of the 2026 benefit year. That distinction matters enormously. A patient with a primary diagnosis of obesity (ICD-10 E66.01) submitting a prior authorization for Saxenda will almost certainly receive a denial under NC Medicaid's current preferred drug list (PDL). A patient with type 2 diabetes (ICD-10 E11.65) seeking Victoza faces a more favorable, though still prior-auth-dependent, review. [3]

NC Medicaid's PDL places liraglutide (Victoza) in the GLP-1 agonist therapeutic class alongside dulaglutide, semaglutide, and exenatide. Preferred status on that list determines whether a step-therapy requirement applies. Step therapy typically means the patient must have failed or contraindicated at least one preferred agent (often metformin and a sulfonylurea) before liraglutide gains approval. [4]

The NC Division of Medical Assistance publishes quarterly PDL updates. Clinicians prescribing liraglutide for Medicaid patients should verify the most current preferred/non-preferred status at the NC Medicaid Clinical Policy and Programs page before initiating a prior authorization. Processing times run 3 to 5 business days for standard requests and 24 hours for expedited urgent appeals under federal Medicaid rules. [5]

For patients seeking liraglutide specifically for weight loss through NC Medicaid, the current policy gap mirrors federal Medicaid law, which historically excluded anti-obesity drugs from coverage. The Treat and Reduce Obesity Act has not been enacted as of this writing, meaning the exclusion remains in place nationally. [6]

Is Compounded Liraglutide Legal in North Carolina?

Compounded liraglutide is legal in North Carolina when dispensed by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a licensed prescriber. The operative legal framework is Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which permits traditional compounding pharmacies to prepare copies of commercially available drugs for individual patients when a prescriber documents a specific clinical need. [7]

The critical compliance nuance: liraglutide is not on FDA's "demonstrably difficult to compound" list, and it does not appear on the FDA's list of drugs withdrawn from market for safety reasons, meaning 503A pharmacies are not categorically prohibited from compounding it. [8] However, the FDA issued warning letters to several 503B outsourcing facilities in 2024 related to GLP-1 compound quality and labeling, and the agency has signaled heightened scrutiny of the entire class. [9]

North Carolina's Board of Pharmacy requires that all 503A pharmacies hold an active NC pharmacy permit and comply with United States Pharmacopeia (USP) 795 standards for nonsterile preparations and USP 797 for sterile preparations. Liraglutide, as a subcutaneous injectable peptide, falls under USP 797 sterile compounding rules. Patients asking a North Carolina telehealth provider to send a compounded liraglutide prescription should verify that the fulfilling pharmacy holds an active NC permit and a current USP 797 accreditation or inspection record. [10]

Compounded liraglutide in North Carolina runs approximately $150 per month through licensed 503A pharmacies, representing roughly an 83% cost reduction versus the brand-name retail cash price. That gap drives significant patient interest, though the FDA has repeatedly noted that compounded drugs are not FDA-approved and have not undergone the same safety and efficacy review as brand-name products. [11]

Which Insurance Plans Cover Liraglutide in North Carolina?

Coverage across commercial insurance plans in North Carolina varies by indication (diabetes vs. obesity), plan tier structure, and employer benefit design. For the type 2 diabetes indication (Victoza), most Blue Cross NC, Aetna, Cigna, and UnitedHealthcare commercial plans cover liraglutide on Tier 3 or Tier 4 of the formulary, with prior authorization required to confirm diagnosis, HbA1c thresholds, and prior metformin use. [12]

For the weight-management indication (Saxenda), employer-sponsored plans in North Carolina may or may not include anti-obesity drug coverage. The Affordable Care Act does not mandate that commercial insurers cover anti-obesity medications, so coverage is entirely plan-specific. A 2023 analysis published in JAMA Network Open found that only 42% of large employer plans in the United States covered at least one GLP-1 agonist for obesity, and that proportion was likely similar or lower in North Carolina's employer market. [13]

ACA marketplace plans sold through HealthCare.gov and the NC state exchange similarly offer variable GLP-1 coverage. Patients should request a Summary of Benefits and Coverage (SBC) from their insurer and specifically ask whether Saxenda or liraglutide appears on the formulary under the obesity/weight management benefit rather than the diabetes benefit; those are often administered as separate tiers with separate authorization pathways.

Medicare Part D covers Victoza for type 2 diabetes but, as of 2025, excludes weight-loss drugs including Saxenda under long-standing CMS policy. [14] The Treat and Reduce Obesity Act, if enacted, would change this, but it has not passed.

Prior authorization approval rates for liraglutide under NC commercial plans improve substantially when the prescriber's letter of medical necessity documents: (1) BMI at or above 30 (or at or above 27 with a weight-related comorbidity per FDA labeling), (2) prior lifestyle intervention failure, and (3) a quantified cardiovascular or metabolic risk. The LEADER trial (N=9,340) demonstrated a 13% reduction in major adverse cardiovascular events with liraglutide versus placebo in patients with established cardiovascular disease (HR 0.87 to 95% CI 0.78 to 0.97, P<0.001 for superiority). [15] Citing that cardiovascular outcome data in prior authorization letters can shift denials to approvals for higher-risk patients.

What Savings Programs Are Available for Liraglutide in North Carolina?

Novo Nordisk operates two distinct savings programs that apply to North Carolina residents paying out of pocket or with commercial insurance. The Saxenda savings card allows commercially insured patients to pay as little as $25 per 30-day supply for up to 24 months, subject to annual cap limits that Novo Nordisk adjusts periodically. Patients with government insurance (Medicaid, Medicare, TRICARE) are explicitly excluded from these commercial card programs. [16]

The Victoza savings card follows a similar structure for diabetes patients, offering copay reduction to as low as $10 per fill per month for eligible commercially insured patients. Both programs require online or phone enrollment at NovoCare.com, and approvals typically process within minutes.

For uninsured or underinsured North Carolinians who do not qualify for those cards, Novo Nordisk's Patient Assistance Program (PAP) provides free medication to patients with household incomes at or below 400% of the federal poverty level. Applications require prescriber signature, proof of income, and confirmation of no existing drug coverage. Turnaround time runs approximately two to four weeks. [17]

The NC MedAssist program and Rx Outreach are third-party North Carolina-based resources that cover select branded medications for low-income patients. Neither program listed liraglutide specifically as a covered drug in their 2025 catalogs, but both accept applications and match patients to manufacturer programs they may have missed.

GoodRx Gold membership ($9.99 per month) lowers liraglutide prices at participating NC pharmacies by an additional 10 to 25% beyond standard GoodRx discounts. Stacking a manufacturer savings card with GoodRx is generally not permitted, but GoodRx can substitute for the savings card at pharmacies where the card has processing issues.

The table below summarizes the four main access pathways for North Carolina patients in 2026, organized by estimated monthly out-of-pocket cost.

| Access Pathway | Estimated Monthly OOP | Eligibility Constraint | |---|---|---| | Brand with Novo savings card (commercial Rx) | $10 to $25 | No government insurance | | Brand cash pay with GoodRx | $700 to $900 | No income limit | | NC Medicaid (T2D diagnosis only) | $0 to $8 copay | Medicaid eligibility + PA approval | | Compounded 503A (telehealth Rx) | ~$150 | Valid prescription required |

Can I Get Liraglutide via Telehealth in North Carolina?

Telehealth prescribing of liraglutide is legal in North Carolina. The state's medical board permits prescribers licensed in North Carolina to initiate and manage controlled substance and prescription-only drug treatment via synchronous audio-video visits, provided a valid prescriber-patient relationship exists. Liraglutide is not a controlled substance, which simplifies the telehealth pathway considerably. [18]

The Ryan Haight Online Pharmacy Consumer Protection Act imposes additional requirements only on Schedule II through V controlled substances; liraglutide falls outside that scope. A North Carolina-licensed prescriber (MD, DO, NP, or PA practicing under a collaborative practice agreement) can therefore issue a valid liraglutide prescription after a video or even audio-only visit that satisfies NC Medical Board standards for a proper evaluation. [19]

HealthRX operates telehealth services in North Carolina. A clinician visit typically includes a structured intake covering weight history, metabolic labs, cardiovascular risk factors, and contraindications to liraglutide (personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, as the FDA label carries a black box warning for thyroid C-cell tumors observed in rodent studies). [20]

After the clinical visit, prescriptions route to either a local NC retail pharmacy or a licensed 503A compounding pharmacy depending on the patient's insurance status, cost preference, and clinical appropriateness. Patients receiving compounded liraglutide through telehealth should confirm the compounding pharmacy's NC permit status before the first shipment.

How Does Liraglutide Work and What Does the Clinical Evidence Show?

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that shares 97% amino acid sequence homology with endogenous human GLP-1. It binds GLP-1 receptors in the pancreas, brain, and gut, producing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite signaling in the hypothalamus. The half-life of approximately 13 hours enables once-daily dosing. [21]

The SCALE Obesity and Prediabetes trial (N=3,731) remains the definitive efficacy dataset for liraglutide 3.0 mg in weight management. Pan et al. and the SCALE investigative group reported in the New England Journal of Medicine (2015) that patients randomized to liraglutide 3.0 mg achieved a mean weight loss of 8.4% versus 2.5% in the placebo group at 56 weeks (P<0.001). [2] More than 63% of liraglutide patients lost at least 5% of body weight compared with 27% in the placebo arm.

The LEADER cardiovascular outcomes trial (N=9,340) demonstrated that once-daily liraglutide 1.8 mg reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% in adults with type 2 diabetes and established or high cardiovascular risk over a median 3.8-year follow-up. [15] The FDA subsequently updated the Victoza label to include a cardiovascular risk reduction indication.

For glycemic control, a Cochrane review of GLP-1 receptor agonists found that liraglutide reduced HbA1c by approximately 1.0 to 1.5 percentage points versus placebo across multiple type 2 diabetes trials, with a favorable weight-loss side effect profile compared with sulfonylureas and insulin. [22]

Common adverse effects include nausea (reported in up to 39.3% of patients in SCALE), vomiting, diarrhea, and constipation, most of which attenuate after the 4-week dose titration period from 0.6 mg to 1.2 mg to 1.8 mg or 3.0 mg. Acute pancreatitis has been reported in postmarketing surveillance; the FDA label recommends discontinuation if pancreatitis is suspected. [20]

What Is the Standard Liraglutide Dose and Titration Schedule?

The FDA-approved titration schedule for Saxenda (obesity indication) starts at 0.6 mg once daily subcutaneously for one week, then increases by 0.6 mg each week until reaching the maintenance dose of 3.0 mg daily. Patients who cannot tolerate 3.0 mg after titration may remain at 2.4 mg if clinically appropriate, though the labeled target is 3.0 mg. [20]

For Victoza (type 2 diabetes), the starting dose is 0.6 mg once daily for one week, titrating to 1.2 mg and then optionally to 1.8 mg based on glycemic response and tolerability. The labeled maximum dose is 1.8 mg for Victoza.

Injection sites include the abdomen, thigh, and upper arm. Liraglutide pens do not require reconstitution and can be used without a sharps-disposal container at home if local regulations permit residential sharps disposal, which North Carolina does permit under the state's Safe Sharps Disposal program. [23]

Patients filling liraglutide at North Carolina pharmacies should store unopened pens refrigerated at 36 to 46 degrees Fahrenheit. Once a pen is in use, it may be stored at room temperature below 86 degrees Fahrenheit or refrigerated for up to 30 days.

Are There Alternatives to Liraglutide in North Carolina That Cost Less?

Semaglutide (Ozempic for T2D, Wegovy for obesity) produces greater mean weight loss than liraglutide at approved doses. STEP-1 (N=1,961) showed semaglutide 2.4 mg once weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo. [24] However, semaglutide carries comparable or higher brand-name list prices than liraglutide, and compounded semaglutide entered a more complicated regulatory environment in 2025 when the FDA declared the shortage resolved, triggering restrictions on 503A and 503B compounding of that molecule.

Dulaglutide (Trulicity) offers once-weekly dosing and covers the T2D indication. Its list price in 2026 runs approximately $900 to $950 per month without insurance, and it appears on more NC commercial formularies as a preferred Tier 2 agent than liraglutide in some plans.

Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist with superior weight-loss efficacy. SURMOUNT-1 (N=2,539) showed up to 22.5% mean weight loss at 72 weeks with tirzepatide 15 mg versus 2.4% with placebo. [25] List price exceeds liraglutide's, though Eli Lilly's savings card program for commercially insured patients can reduce monthly cost to $25 to $50.

For patients with T2D and cost as the primary constraint, generic metformin (under $10 per month at most NC pharmacies) and generic glipizide or glyburide remain options, though they do not produce the weight loss or cardiovascular risk reduction seen with GLP-1 agents.